Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 90 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viral Upper Respiratory Infection Clear all
Completed No phase listed Observational Results available

The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years

NCT00405509
View directory record Official record
Conditions
Upper Respiratory Infection, Common Cold
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 13 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jul 23, 2026, 3:02 PM EDT
Completed No phase listed Observational

Diagnosing Respiratory Disease in Children Using Cough Sounds 2

NCT03392363
View directory record Official record
Conditions
Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup, Reactive Airway Disease, Upper Respiratory Disease, Viral Lower Respiratory Tract Infections, Lower Respiratory Disease
Interventions
Recordings of Infants and Children's Cough Sounds
Device
Lead sponsor
ResApp Health Limited
Industry
Eligibility
29 Days to 12 Years
Enrollment
1,470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Jul 23, 2026, 3:02 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of A Lotion to Prevent Common Colds

NCT00993759
View directory record Official record
Conditions
Common Cold, Healthy
Interventions
3804-250A
Drug
Lead sponsor
The Dial Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2009 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Galactooligosaccharide, Immune Strength, and Digestive Health

NCT01137760
View directory record Official record
Conditions
Healthy
Interventions
Sucrose, Galactooligosaccharide
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

NCT00091702
View directory record Official record
Conditions
HIV Infections, Influenza
Interventions
Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

NCT00189475
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Deborah Gentile
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jul 23, 2026, 3:02 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Elderberry for Immune Support

NCT05435144
View directory record Official record
Conditions
Upper Respiratory Tract Infection, COVID-19, Flu, Flu Like Illness, Cold
Interventions
Elderberry, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
20 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial

NCT00745849
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
esomeprazole, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 23, 2026, 3:02 PM EDT
Terminated Not applicable Interventional Results available

Botulinum Toxin A for Herpes Labialis

NCT01225341
View directory record Official record
Conditions
Herpes Labialis
Interventions
onabotulinumtoxinA, Bacteriostatic normal saline
Drug · Other
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 23, 2026, 3:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nasal Swab Study to Explore the Nasal Microbia

NCT02535442
View directory record Official record
Conditions
Common Cold
Interventions
Not listed
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

NCT00415493
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
Cold-dry air provocation, Warm-moist air provocation
Other
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 23, 2026, 3:02 PM EDT
Terminated Phase 4 Interventional Results available

Acute Cough Study In Children

NCT01257542
View directory record Official record
Conditions
Common Cold, Infections, Upper Respiratory Tract
Interventions
Dextromethorphan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Pinellas Park, Florida • Indianapolis, Indiana • Gresham, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Jul 23, 2026, 3:02 PM EDT
Not listed Phase 4 Interventional

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

NCT00406094
View directory record Official record
Conditions
Rhinitis
Interventions
montelukast, placebo
Drug
Lead sponsor
Bernstein, Jonathan A., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2009 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional

Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

NCT00469300
View directory record Official record
Conditions
Herpes Labialis
Interventions
Iontophoretic delivery of acyclovir
Drug
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Rosa, California • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2008 · Synced Jul 23, 2026, 3:02 PM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

NCT00762476
View directory record Official record
Conditions
Common Cold
Interventions
3804-250A, 3804-291
Drug
Lead sponsor
The Dial Corporation
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Paramus, New Jersey • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Jul 23, 2026, 3:02 PM EDT
Completed No phase listed Observational

An Observational Study to Evaluate The Relationship of Nasal Mucus Properties and Symptoms

NCT01553110
View directory record Official record
Conditions
Acute Rhinosinusitis, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jul 23, 2026, 3:02 PM EDT
Withdrawn No phase listed Observational

ImmuneSense™ COVID-19 Cross-Reactivity Study

NCT05112874
View directory record Official record
Conditions
Coronavirus Disease, SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 23, 2026, 3:02 PM EDT
Not listed Not applicable Interventional

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

NCT02759900
View directory record Official record
Conditions
Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea, Molluscum Contagiosum, Bowen's Disease, Warts
Interventions
Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Clinical Study for the Treatment of Cold Sore

NCT00769314
View directory record Official record
Conditions
Herpes Labialis
Interventions
Acyclovir Lauriad, Placebo
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Results available

The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

NCT05093478
View directory record Official record
Conditions
Non-allergic Rhinitis
Interventions
Intranasal capsaicin, topical lidocaine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Jul 23, 2026, 3:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

NCT05447078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 23, 2026, 3:02 PM EDT